Raymond James & Associates Compugen LTD Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Compugen LTD stock. As of the latest transaction made, Raymond James & Associates holds 83,825 shares of CGEN stock, worth $176,870. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,825
Previous 84,625
0.95%
Holding current value
$176,870
Previous $142,000
6.34%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding CGEN
# of Institutions
78Shares Held
16.4MCall Options Held
59.3KPut Options Held
32.1K-
Silverarc Capital Management, LLC3.03MShares$6.4 Million1.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.33MShares$2.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.31MShares$2.77 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl1.07MShares$2.26 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C31.02MShares$2.15 Million0.0% of portfolio
About COMPUGEN LTD
- Ticker CGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 86,624,600
- Market Cap $183M
- Description
- Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...